Profile data is unavailable for this security.
About the company
PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.
- Revenue in GBP (TTM)356.82k
- Net income in GBP-62.87m
- Incorporated2015
- Employees90.00
- LocationPureTech Health PLC6 Tide Street, Suite 400BOSTON 02210United StatesUSA
- Phone+1 (617) 482-2333Fax+1 (617) 482-3337
- Websitehttps://puretechhealth.com/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
Futura Medical PLC | 8.40m | -3.75m |
Scancell Holdings Plc | 0.00 | -5.86m |
4Basebio PLC | 596.00k | -9.84m |
Avacta Group Plc | 22.62m | -25.89m |
hVIVO PLC | 64.38m | 17.45m |
Bioventix PLC | 13.60m | 8.67m |
Allergy Therapeutics plc | 53.26m | -50.22m |
Faron Pharmaceuticals Oy | 0.00 | -26.45m |
Puretech Health PLC | 356.82k | -62.87m |
Oxford BioMedica plc | 97.28m | -142.02m |
Genus plc | 668.80m | 7.90m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Invesco Asset Management Ltd.as of 25 Jun 2024 | 41.00m | 15.14% |
Lansdowne Partners (UK) LLPas of 31 Mar 2023 | 24.37m | 9.00% |
Baillie Gifford & Co.as of 31 Mar 2023 | 22.52m | 8.32% |
Jupiter Asset Management Ltd.as of 15 Jul 2020 | 14.25m | 5.26% |
M&G Investment Management Ltd.as of 31 Mar 2023 | 11.76m | 4.34% |
Miller Value Partners LLCas of 31 Mar 2021 | 10.04m | 3.71% |
Patient Capital Management, Inc.as of 31 Mar 2023 | 9.81m | 3.62% |
Eurizon Capital SGR SpAas of 01 Jul 2024 | 9.56m | 3.53% |
Patient Capital Management LLC (Invt Mgmt)as of 28 Jun 2024 | 8.41m | 3.11% |
The Vanguard Group, Inc.as of 01 Jul 2024 | 5.41m | 2.00% |